Radically different
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
A startup called Varda Space Industries is betting that the future of pharmaceuticals lies in orbit. The company has signed a deal with United Therapeutics to test whether drugs crystallize differently in microgravity, potentially creating improved versions with new properties.
The idea sounds futuristic, but falling launch costs and reusable rockets are making space-based manufacturing seem increasingly plausible. Varda says the partnership could mark an important step toward building products in orbit for use back on Earth.
Discover how space could become the next frontier for drug development.
—Antonio Regalado
Just before Artemis II began its historic slingshot around the moon, NASA revealed an even grander space travel plan. By the end of 2028, the agency aims to fly a nuclear reactor-powered interplanetary spacecraft to Mars.
A successful mission would herald a new era in spaceflight—and might just give the US the edge in the race against China. But the project remains shrouded in mystery.
MIT Technology Review picked the brains of nuclear power and propulsion experts to find out how the nuclear-powered spacecraft might work.
—Robin George Andrews
This is our latest story to be turned into an MIT Technology Review Narrated podcast, which we publish each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 Sam Altman claims Elon Musk tried to seize control of OpenAI
Altman said Musk initially wanted 90% of the equity. (AFP)
+ And that control should go to his children when he dies. (BBC)
+ Altman also accused Musk of twice trying to end its non-profit status. (NPR)
+ Musk’s motivations for the suit are under scrutiny. (MIT Technology Review)
2 Google and SpaceX are in talks to launch data centers into orbit
SpaceX could join Suncatcher, Google’s orbital data center project. (WSJ $)
+ The project’s first launch is slated for early 2027. (Guardian)
+ Anthropic and SpaceX have also discussed orbital data centers. (Wired $)
+ But there are a few hurdles to overcome. (MIT Technology Review)
3 Jensen Huang has joined Donald Trump’s high-stakes mission to China
Nvidia is lobbying to sell its AI chips in the country. (Bloomberg $)
+ Elon Musk and Tim Cook are also on the trip. (CNBC)
+ But a tech rivalry and distrust have sapped hopes for big deals. (Reuters $)
4 ICE agents have a list of 20 million people on their iPhones, thanks to Palantir
An ICE official said Palantir is speeding up raids and arrests. (404 Media)
+ ICE has also used facial recognition and Paragon spyware. (TechCrunch)
5 Defense tech firm Anduril just doubled its valuation to over $60 billion
In a $5 billion funding round led by Thrive Capital and a16z. (FT $)
Anduril, which makes AI-backed weapons, may go public next year. (NYT $)
6 Meta employees are protesting computer-tracking at work
Flyers posted at offices are urging staff to oppose the program. (Reuters $)
+ Meta plans to track workers’ clicks and keystrokes to train AI. (CNBC)
7 OpenAI is facing another wrongful death lawsuit over ChatGPT medical advice
The chatbot’s tips allegedly led to a teenager’s overdose. (Ars Technica)
8 The Canvas learning platform has paid hackers to delete stolen student data
It caved to ransomware demands after the biggest-ever edtech breach. (BBC)
9 Scientific researchers are thinking twice about using AI
Due to price hikes, usage limitations, and unreliable outputs. (Nature)
10 The latest AI compute solution? Putting data centers in your home
Hardware hosts get subsidized electricity and internet. (Ars Technica)
Quote of the day
—Sam Altman claims that Elon Musk tried to destroy rather than protect OpenAI’s non-profit operations, the Guardian reports.
One More Thing
Chatbot fails are now a familiar meme. Meta’s short-lived scientific chatbot generated wiki articles about the history of bears in space. Lawyers have submitted court documents filled with legal citations fabricated by ChatGPT. Air Canada was ordered to honor a refund policy invented by its customer service chatbot.
This tendency to make things up—known as hallucination—is one of the biggest obstacles holding chatbots back from more widespread adoption. Here’s why they do it—and why we still can’t fix it.
—Will Douglas Heaven
This story is part of MIT Technology Review Explains, our series untangling the complex, messy world of technology to help you understand what’s coming next. You can read more from the series here.
We can still have nice things
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ A historian has unearthed the etymology of every single dinosaur name.
+ Humus on the moon is getting closer to reality after scientists grew chickpeas in lunar soil.
+ Witness the patience of a master paper artist in this gallery of intricate, handmade sculptures.
+ Want to tell the time alphabetically? Me neither, but this cursed clock is an intriguing reason to try.
For highly aggressive types of blood cancer, stem cell transplantation is often the only potentially curative therapy. Yet, these cancers can often return even after a transplant. Notably, CAR T cell therapy has not been effective against all blood cancers, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
A recent Phase I/II multicenter clinical trial, led by researchers at Washington University School of Medicine in St. Louis, shows that a stem cell transplant, that removes CD33 from donor cells using CRISPR, can help prevent cancer recurrence.
The work was published in Nature Medicine and titled, “CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a Phase I/II trial.” The study was conducted at Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, and 14 other sites in the U.S. and Canada. 30 adult patients with AML or MDS at high risk of relapse received the stem cell transplant.
Myeloid cancers, such as AML and MDS, are difficult to treat with CAR T cells because the same proteins targets are present on both cancer cells and healthy myeloid cells, leading to toxicity risks.
“We are encouraged by the results of this study showing that a CD33-deleted stem cell transplant looks very similar to the outcomes of standard stem cell transplantation,” said John DiPersio, MD, PhD, professor of medicine at WashU Medicine and corresponding author of the study. “In the future, we are hopeful we will be able to combine this with CD33-targeted immunotherapies, such as CAR T cells, and improve treatment options for patients with these very aggressive blood cancers.”
As proof of concept, patients also received a maintenance therapy that targets CD33, after completion of the stem cell transplant. While not a CD33-targeted CAR T cell, the maintenance therapy, called gemtuzumab ozogamicin, is an engineered antibody that targets CD33 and carries an anti-cancer drug. Gemtuzumab ozogamicin is approved by the Food and Drug Administration (FDA) to treat CD33-positive AML and is in clinical trials for CD33-positive MDS. While it helps prevent relapse, the drug’s use is limited because it can cause liver toxicity and damage to blood cells, including dangerously low counts of white blood cells, red blood cells, and platelets.
All patients from the trial achieved engraftment of their transplanted stem cells by day 28. Some patients met this goal sooner with platelet production returning by day 16 on average. These timeframes are comparable to those of standard transplanted stem cells.
Average survival was just over 14 months. Nineteen patients received at least one cycle of the antibody maintenance therapy as part of a dose-escalation protocol. The authors found that patients maintained blood cell counts across all doses, suggesting that the gene-edited stem cell transplant protected patients from low blood cell counts typically seen following a standard stem cell transplant.
DiPersio and colleagues published a single case study detailing a patient with high-risk AML who received a CD33-deleted stem cell transplant. Upon relapse after the transplant, the patient received a CD33-targeted CAR T cell therapy, which used T cells from the same donor who provided the stem cell transplant.
The treatment resulted in complete remission and the patient remains cancer free over one year after receiving the CAR T cell therapy. Normal blood cell production returned with all blood cells lacking CD33, providing evidence that the genetically engineered donor cells had established themselves in the bone marrow.
DiPersio said the results of the study lay the groundwork for developing paired CD33-deleted stem cell transplant and CD33-targeted immunotherapy interventions that avoid destruction of healthy donor cells in the course of cancer treatment.
The post Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant appeared first on GEN – Genetic Engineering and Biotechnology News.
Women with endometriosis have a small but significant increased risk for having babies with birth defects, such as those affecting the heart, gastric, genital, or musculoskeletal system, compared with women without the condition.
As reported in the Canadian Medical Association Journal, 6.3% of infants born to women with endometriosis included in the study had a congenital anomaly, compared with 5.4% of infants born to those without the condition.
Notably, only around 11% of the increased risk could be attributed to fertility treatment meaning that the condition itself is likely responsible for the small increase in risk. It suggests that endometriosis itself, likely through inflammatory pathways, oxidative stress, or epigenetic mechanisms, may directly disrupt fetal organogenesis.
Endometriosis is a chronic condition where tissue similar to the uterine lining grows outside the uterus, causing severe pelvic pain, painful periods, and often infertility. It affects an estimated 6.5 million women in the U.S., though many go undiagnosed for years.
“Endometriosis can trigger inflammation and oxidative stress, which have been linked to abnormal organogenesis in offspring. This disruption in organogenesis can lead to functional or structural anomalies that occur in utero, which typically develop in the first trimester of gestation,” write lead author Bailey Milne, Queen’s University, Kingston, Ontario, and colleagues.
“Some studies have reported an increased risk of genital defects among infants born to women with endometriosis; however, data are lacking on the risk of other congenital anomalies.”
To investigate this further, Milne and team conducted a large population-based cohort study using Ontario health administrative data, examining over 1.46 million births between 2006 and 2021. The aim was to quantify the risk of congenital anomalies in infants born to women with a pre-existing diagnosis of endometriosis.
Overall, 33,619 (2.3%) women included in the study had endometriosis. Women with endometriosis had a 16% increase in risk for having a baby with a congenital birth defect compared with women without the condition and 89% of this risk could be attributed to the presence of endometriosis and not possible confounding factors like fertility treatment. The most common associated defects were cleft palate, male genitourinary malformations, and cardiovascular abnormalities.
“Although this study contributes to accumulating data on a potential increased risk of birth defects for infants born to patients with endometriosis, the specific mechanistic pathways remain largely unknown,” write Milne and coauthors.
“A theorized mechanism by which endometriosis might increase risk of any congenital anomaly is through inflammatory pathways. The existing literature suggests a need for more comprehensive models that integrate genetic, epigenetic, and environmental factors to better understand this.”
The post Endometriosis May Increase Risk of Birth Defects appeared first on Inside Precision Medicine.
Background: Neurorehabilitation plays a key role in improving motor recovery for people with neurological conditions. Although 3D printing has emerged as a promising rehabilitation tool, little is known on how it is used for the rehabilitation of adults living with neurological conditions worldwide. Objective: We aimed to provide a comprehensive overview of 3D printing in neurorehabilitation and precisely explore how it is used to improve motor recovery for adults with neurological conditions living in higher- and lower-middle–income countries. Methods: We conducted a scoping review following the Joanna Briggs Institute guidelines. After searching 3 databases (MEDLINE, Web of Science, and Nursing and Allied Health Premium), 2 independent reviewers screened and selected English-language studies involving adults (≥18 years) published between 2019 and 2024 to capture the most recent advancements in this field. We extracted relevant information on neurological conditions, motor recovery outcomes, and types of 3D printing and offered a comparative analysis of 3D printing in physical neurorehabilitation from the perspective of national income levels using a modified Joanna Briggs Institute extraction form. We synthesized the findings narratively with tabular support. Results: After screening 2752 titles and abstracts and 103 (3.7%) full texts, we included 13 (0.5%) studies based on our inclusion criteria. All included studies were conducted in upper-middle–income or high-income countries, and most studies (9/13, 69.2%) focused on stroke, followed by spinal cord injury (2/13, 15.4%), Parkinson disease (1/13, 7.7%), and central nerve disease (1/13, 7.7%). The 3D-printed rehabilitation tools included orthotics (7/13, 53.8% for the upper extremities [UEs]; 3/13, 23.1% for the lower extremities [LEs]), an exoskeleton (1/13, 7.7%; UEs), a modular assistive hand device (1/13, 7.7%; UEs), and an insole (1/13, 7.7%; LEs). In total, 69.2% (9/13) of the studies targeted UE rehabilitation, measured using the Action Research Arm Test, active range of motion, the box and block test, the Fugl-Meyer Assessment, the Modified Ashworth Scale, the manual function test, range of motion, and the Toronto Rehabilitation Institute Hand Function Test, and 30.8% (4/13) targeted LE rehabilitation, measured using the 10-m walk test, anteroposterior ground reaction force analysis, the Barthel index, the Tinetti scale, the RehaWatch system, and the GaitWatch system. Conclusions: Used as a rehabilitation tool, 3D printing technology has demonstrated significant potential in improving upper and lower motor recovery for people with certain neurological conditions in high-middle–income countries. Future research should explore the implementation feasibility and effectiveness of these technologies across different neurological conditions and income settings, particularly in low- and lower-middle–income countries.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/11352972abf74214e055b465780e25ce" />
Researchers at the Institut National de la Recherche Scientifique in Montreal have found that compounds in cranberry juice may enhance the effectiveness of a commonly used antibiotic for urinary tract infections (UTIs) by altering how bacteria take up the drug. The findings, published in Applied and Environmental Microbiology, show that cranberry juice increased the activity of fosfomycin against uropathogenic Escherichia coli (UPEC) in laboratory testing and reduced the emergence antibiotic resistance mutations in 72% of the E. coli strains studied.
While the findings are encouraging, the researchers noted that the work didn’t show whether consumption of cranberry juice would have the same effects as those shown in the lab. “We don’t know if the metabolites will reach the infection,” said lead author Eric Déziel, PhD, a professor at Institut National de la Recherche Scientifique. “But if they could, then juice may increase the efficacy of antibiotic treatment.”
UTIs are most often caused by UPEC, which accounts for the majority of community-acquired infections and a substantial proportion of catheter-associated infections. Standard treatments include antibiotics such as trimethoprim-sulfamethoxazole, nitrofurantoin, and fosfomycin. While fosfomycin is a recommended first-line therapy because of its broad activity and low resistance rates, past studies have shown that some resistant variants can emerge through mutations that influence bacterial transport systems.
Cranberry products have long been associated with UTI prevention. Earlier theories surmised this was due to fruit’s acidity. Subsequent research, however, has identified specific compounds, including proanthocyanidins and fructose, that interfere with the ability of bacterial to attach to cells lining the urinary tract.
Déziel said that cranberry juice has a long history as folk remedy for preventing and treating urinary tract infections. It was the recent finding of the anti-adhesive properties that prompted further investigation into whether cranberry could influence antibiotic performance.
To test this, the research team exposed 32 clinical isolates of UPEC to cranberry juice in combination with fosfomycin under controlled laboratory conditions. The results showed that in 72% of the strains tested, cranberry juice increased the antibiotic’s inhibitory activity. At the same time, the frequency of spontaneous mutations conferring resistance dropped substantially, in some cases by several orders of magnitude.
The effects of the cranberry juice seems to involve changes in how bacterial cells regulate the uptake of sugars and, by extension, the antibiotic since fosfomycin enters bacterial cells through carbohydrate transport systems, primarily the GlpT and UhpT pathways. Resistance often arises when mutations reduce the activity of these transporters, which then limits the drug entering cells.
Specifically, cranberry juice reduced expression of the GlpT transporter while maintaining or promoting activity through the UhpT system. This shift allowed fosfomycin into the bacterial cell even as other pathways were downregulated. Reporter assays showed that this change sustained antibiotic uptake, while genomic sequencing revealed distinct mutation patterns depending on whether cranberry juice was present.
While the researchers were able to characterize the activity related to the presence of cranberry juice, the compounds responsible for this effect have not been fully identified. Déziel noted that “something in the cranberry juice” induces bacteria to increase uptake through one of these channels, leading to greater absorption of fosfomycin. Previous research has pointed to cranberry-derived molecules that interact with bacterial communication and adherence systems, but their role in modulating antibiotic transport has not been identified.
The study builds on earlier work from Déziel’s lab showing that cranberry extracts can act synergistically with antibiotics. The current research showed that this is also the case with cranberry juice itself. The hope is that simply consuming cranberry juice could produce the same effects as the extracts studied previously.
Despite the promising laboratory data, the researchers said that the findings cannot yet be translated to the clinic. It is still unclear whether the active compounds in cranberry juice are found at the needed concentrations in the urinary tract after consumption, or how much juice would be required to produce a measurable effect.
Future research will seek to identify the specific compounds responsible for the effects shown in this study, determine how they behave in vivo, and assess whether they can be incorporated into treatment strategies.
The post Natural Compounds in Cranberry Juice May Enhance Antibiotic Treatment of UTIs appeared first on Inside Precision Medicine.